Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and uses thereof
Bayer Pharma Aktiengesellschaft
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/EP2013/059618, filed May 8, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,040,866 | Nucleic Acids and Host Cells Expressing Antibodies Capable of Binding to the Coagulation Factor Xia and Uses Thereof In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | ||
| US 10,221,247 | Antibodies Capable of Binding to the Coagulation Factor Xia and Uses Thereof In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | ||
| US 11,046,783 | Antibodies Capable of Binding to the Coagulation Factor Xia and Uses Thereof In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | ||
| US 9,783,614 | Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and uses thereof In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.